<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Exp Ther Med</journal-id><journal-id journal-id-type="iso-abbrev">Exp Ther Med</journal-id><journal-id journal-id-type="publisher-id">ETM</journal-id><journal-title-group><journal-title>Experimental and Therapeutic Medicine</journal-title></journal-title-group><issn pub-type="ppub">1792-0981</issn><issn pub-type="epub">1792-1015</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6257438</article-id><article-id pub-id-type="doi">10.3892/etm.2018.6822</article-id><article-id pub-id-type="publisher-id">ETM-0-0-6822</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>The role of PI3-K/Akt signal pathway in the antagonist effect of CEPO on CHF rats</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Zhaoqi</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-6822">1</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="af2-etm-0-0-6822">2</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Jinlei</given-names></name><xref ref-type="aff" rid="af3-etm-0-0-6822">3</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Shengqiang</given-names></name><xref ref-type="aff" rid="af4-etm-0-0-6822">4</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Ximing</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-6822">1</xref><xref rid="c1-etm-0-0-6822" ref-type="corresp"/></contrib></contrib-group><aff id="af1-etm-0-0-6822"><label>1</label>Department of Cardiovascular Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510150, P.R. China</aff><aff id="af2-etm-0-0-6822"><label>2</label>Department of Cardiovascular Medicine, Huadu District People's Hospital of Guangzhou, Guangzhou, Guangdong 510000, P.R. China</aff><aff id="af3-etm-0-0-6822"><label>3</label>Department of Cardiovascular Medicine, Hexian Memorial Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong 510000, P.R. China</aff><aff id="af4-etm-0-0-6822"><label>4</label>Institute for Neurological Research, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510260, P.R. China</aff><author-notes><corresp id="c1-etm-0-0-6822"><italic>Correspondence to</italic>: Dr Ximing Chen, Department of Cardiovascular Medicine, The Third Affiliated Hospital of Guangzhou Medical University, 63 Duobao Road, Liwan, Guangzhou, Guangdong 510150, P.R. China, E-mail: <email>18078805442@163.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>02</day><month>10</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>02</day><month>10</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>16</volume><issue>6</issue><fpage>5161</fpage><lpage>5165</lpage><history><date date-type="received"><day>08</day><month>3</month><year>2018</year></date><date date-type="accepted"><day>11</day><month>9</month><year>2018</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Huang et al.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><abstract><p>The possible role of phosphoinositide 3-kinase (PI3-K)/protein kinase B (Akt) signal pathway in the antagonist effect of carbamylated erythropoietin (CEPO) on chronic heart failure (CHF) in rats was investigated. Twenty of 120 rats were randomly selected as the control group, and the remaining rats as the model group. Rats in the model group received intraperitoneal injection of isoproterenol, those in the control group underwent intraperitoneal injection of equivalent normal saline. Rats with successful model establishment were divided into 4 groups, i.e. CHF group, CEPO group, LY294002 (LY) group and CEPO + LY group. Rats in the CEPO group underwent intraperitoneal injection of CEPO, while those in the CHF group received intraperitoneal injection of equivalent normal saline at the same time, those in the LY group received intraperitoneal injection of LY after model establishment, and those in the CEPO + LY group received the combined intraperitoneal injection of CEPO and LY simultaneously. Indicators for hemodynamics were determined using BL-410S bio-functional experiment system, including heart rate (HR), left ventricular end-diastolic pressure (LVEDP), left ventricular systolic pressure (LVSP) and maximal increased rate of left ventricular pressure (LVP)/maximal reduced rate of LVP (&#x000b1;dp/dt<sub>max</sub>). Western blotting assay was utilized to determine the changes in activity of PI3-K/Akt signal pathway. LVSP and &#x000b1;dp/dt<sub>max</sub> in the CHF, the CEPO, the CEPO + LY and the LY groups were significantly lower than those in the control group (P&#x0003c;0.05); LVSP and &#x000b1;dp/dt<sub>max</sub> in the CEPO group were also elevated significantly compared with CHF, LY and CEPO + LY groups (P&#x0003c;0.05) with significant decreases in LVEDP and HR (P&#x0003c;0.05); compared with the CHF group, LVSP and &#x000b1;dp/dt<sub>max</sub> in the LY group were each significantly decreased (P&#x0003c;0.05), in the LY group, pAkt level was significantly lower than that in the CHF group (P&#x0003c;0.05). In conclusion, CEPO can generate the antagonist effect on CHF in rats through activation of PI3-K/Akt signal pathway.</p></abstract><kwd-group><kwd>CHF</kwd><kwd>CEPO</kwd><kwd>hemodynamics</kwd><kwd>PI3-K/Akt</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>With an aging population in the world, incidence rate of chronic heart failure (CHF) has been increasing year by year, resulting in an elevation in mortality rate (<xref rid="b1-etm-0-0-6822" ref-type="bibr">1</xref>). CHF, as the end-stage of many cardiovascular diseases, refers to a clinical syndrome caused by organic or functional variations in the heart with major manifestations such as anomaly in heart structure, decrease in cardiac output caused by dysfunction of ventricular filling and/or ejection, persistent increase in venous pressure and gradual dysfunction in hemodynamics that can hardly satisfy the requirement of metabolism, which can result in progressive exacerbation in heart failure, necrosis in myocardial cells, thereby threatening the health and life quality of human beings; according to the degree of failure, CHF can be divided into three types: Left heart failure, right heart failure and whole heart failure (<xref rid="b2-etm-0-0-6822" ref-type="bibr">2</xref>). Besides, some younger patients may be the victims of CHF, and, though CHF can be controlled by treatment, these patients are more susceptible to the recurrence of CHF for its irreversible and refractory features (<xref rid="b3-etm-0-0-6822" ref-type="bibr">3</xref>). Although inhibitor of renin-angiotensin system (RAS) is dominant in treatment of heart failure with the ability to stabilize or decrease the pressure and the protective effect on target organs, it brings about a variety of inevitable adverse reactions (<xref rid="b4-etm-0-0-6822" ref-type="bibr">4</xref>). Thus, searching for a new kind of drug with prominent efficacy and mild side effect is necessary.</p><p>In humans, erythropoietin (EPO), a glycoprotein secreted by kidneys, can bind to EPO receptor (EPOR) specifically, thereby activating the proliferation and differentiation of erythrocytes (<xref rid="b5-etm-0-0-6822" ref-type="bibr">5</xref>). Enormous number of studies have indicated that in addition to the function to activate the hematopoiesis, EPO manifests a protective activity on myocardial cells (<xref rid="b6-etm-0-0-6822" ref-type="bibr">6</xref>). EPO, through binding to EPOR, can activate EPOR to initiate multiple signal transduction pathways, like signal transducer and activator of transcription 5 (STAT5), phosphoinositide 3-kinase (PI3-K)/protein kinase B (Akt, or PKB) signal pathway, or mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signal pathway, thereby protecting the tissues extensively (<xref rid="b7-etm-0-0-6822" ref-type="bibr">7</xref>). Not only can EPO protect the heart through increasing the oxygen supply to tissues by activating the generation of erythrocytes, but also it can exert its protective effect on the heart through multiple ways, including anti-apoptosis, anti-inflammation and pro-angiogenesis effects (<xref rid="b8-etm-0-0-6822" ref-type="bibr">8</xref>). Thereupon, medicinal EPO has been applied in treatment of relevant diseases, but, when applied as the protective agent, the dose of EPO should be higher than that in treatment of anemia (<xref rid="b9-etm-0-0-6822" ref-type="bibr">9</xref>), and such a high dose of EPO may give rise to dose-dependence, increased risks in coagulation and thrombosis, or even exacerbation in heart failure, which may frequently occur particularly in patients at high risk with thrombus, hypertension, polycythemia or hyperviscosity syndrome (<xref rid="b10-etm-0-0-6822" ref-type="bibr">10</xref>). Due to the adverse reactions above, application of EPO has been largely limited in clinical treatment of cardiovascular diseases. In 2004, Fiordaliso <italic>et al</italic> (<xref rid="b11-etm-0-0-6822" ref-type="bibr">11</xref>) in an <italic>in vitro</italic> experiment obtained carbamylated erythropoietin (CEPO), a derivative of EPO, which retains anti-inflammation, anti-apoptosis and tissue-protective effects that are similar to EPO but without pro-hematopoietic effect. CEPO is much safer than EPO in treatment of cardiovascular diseases with a much wider application prospect (<xref rid="b11-etm-0-0-6822" ref-type="bibr">11</xref>).</p><p>PI3-K/Akt (also called PKB) is a major signal pathway delivering the signal of anti-apoptosis/pro-proliferation, and PI3-K plays a key role in signal transduction pathway mediated by the growth factor receptor superfamily (<xref rid="b12-etm-0-0-6822" ref-type="bibr">12</xref>). Through binding to EPOR, EPO can activate PI3-K that will further catalyze the transformation of diphosphoinositide (PIP2) into triphosphoinositide (PIP3), which, as a second messenger, can activate the following multiple target proteins, thereby regulating the proliferation, differentiation, migration and transplantation of cells (<xref rid="b13-etm-0-0-6822" ref-type="bibr">13</xref>). Akt, also called serine/threonine protein kinase B (PKB), is one of the downstream target proteins of PI3-K; once activated, Akt can be phosphorylated into phosphorylated Akt (pAkt), which can further phosphorylate a series of apoptotic regulation factors of B-cell lymphoma-2 (Bcl-2)/ B-cell lymphoma-extra-large (Bcl-XL)-associated death promoter (BAD), caspase and nuclear factor (NF)-&#x003ba;B, so as to affect the transcription of anti-apoptosis genes, which is conducive to survival of cells (<xref rid="b14-etm-0-0-6822" ref-type="bibr">14</xref>). In this study, we investigated whether CEPO could antagonize CHF in rats through the PI3-K/Akt signal pathway.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Materials</title><sec><title>Experimental animals</title><p>A total of 120 healthy clean male Wistar rats weighing 200&#x02013;240 g were purchased from Experimental Animal Center of Academy of Military Medical Sciences (Beijing, China) [approval no. SCXK-(Military) 2012 0004] and fed with regular food in separate cages at 20&#x02013;25&#x000b0;C and 60&#x02013;70% humidity-controlled environment, in which rats had free access to water that was disinfected through ultraviolet. Adjustment in light and ventilation was performed in accordance with the standards. Padding was changed twice per week, and regular food was given in 25 g/rat/day. Experiment was carried out following several days of acclimatization. The study was approved by the Ethics Committee of The Third Affiliated Hospital of Guangzhou Medical University (Guangzhou, China).</p></sec><sec><title>Reagents</title><p>Before administration of CEPO (Amgen, Thousand Oaks, CA, USA), the dose of CEPO was calculated and weighed in 50 &#x000b5;g/kg with reference of the total weight of rats in CEPO group. Then CEPO was dissolved in double distilled water until well mixed, and the concentration of CEPO was adjusted to 100 &#x000b5;g/ml; isoproterenol (ISO; 2 ml, 1 mg/bottle, Shanghai Harvest Pharmaceutical Co. Ltd., Shanghai, China); LY294002 (LY) (Selleck Chemicals, Houston, TX, USA); enhanced chemiluminescence (ECL) kit (Santa Cruz Biotechnology, Inc., Dallas, TX, USA); Rabbit anti-rat pAkt (Ser473) and Akt monoclonal antibodies (cat. nos. 4058 and 4685 respectively; Cell Signaling Technology, Inc., Danvers, MA, USA); horseradish peroxidase labeled anti-rabbit IgG polyclonal antibody (cat. no. 7074; Cell Signaling Technology, Inc.). Bicinchoninic acid (BCA) protein assay reagent kit (Pierce; Thermo Fisher Scientific, Inc., Waltham, MA, USA).</p></sec></sec><sec><title>Methods</title><sec><title>Establishment of CHF models in rats</title><p>After being fed for several days to acclimatize to the environment, 20 of the rats were selected as the control group, and the remaining rats as the model group, where rats underwent intraperitoneal injection of ISO (5 mg/kg) once per day for 3 days to establish the models. At the same time, rats in the control group underwent intraperitoneal injection of equivalent normal saline. During intraperitoneal injection, needle should be inserted into the abdomen. Pumped back to see whether the blood or intestinal fluid was drawn, so as to avoid the drugs being delivered into the vessels, which could lead to the death of rats, or into the bladder or intestinal tube to lose the activity of drugs. After 5 weeks of feeding, survived rats were delivered to evaluate the model establishment. During the feeding period, a total of 8 rats in the model group died, which might have been caused by the rapid injection of ISO or delivery of drugs to vessels due to inappropriate operations, leading to embolism, or any other unknown factors. In examination of hemodynamics, left ventricular end-diastolic pressure (LVEDP) &#x02265;15 mmHg suggested that models were established successfully (<xref rid="b15-etm-0-0-6822" ref-type="bibr">15</xref>).</p></sec><sec><title>Grouping of animals</title><p>After the hemodynamics examination for identifying the successful model establishment, wounds in rats were sutured followed by administration of gentamycin at a dose of 24,000 U/kg/day for 3 days to prevent infections. A total of 92 rats with successful model establishment were divided into 4 groups randomly, i.e. CHF group (n=23), CEPO group (n=23), LY group (n=23) and CEPO + LY group (n=23).</p><p>CEPO group: After being weighed, rats in CEPO group underwent intraperitoneal injection of CEPO at a dose of 50 &#x000b5;g/kg for 4 weeks (<xref rid="b16-etm-0-0-6822" ref-type="bibr">16</xref>).</p><p>CHF group and control group: Rats in CHF group received intraperitoneal injection of equivalent normal saline at the same time.</p><p>The rats in LY group, after being weighed, received intraperitoneal injection of LY at a dose of 0.25 &#x000b5;g/100 g twice per week for 4 weeks.</p><p>Rats in CEPO + LY group, after being weighed, received intraperitoneal injection of LY at a dose of 0.25 &#x000b5;g/100 g firstly for pretreatment followed by intraperitoneal injection of CEPO at a dose of 50 &#x000b5;g/kg twice per week for 4 weeks.</p><p>After 4 weeks, indicators for hemodynamics were determined in all survived rats, including heart rate (HR), LVEDP, left ventricular systolic pressure (LVSP) and maximal increased rate of left ventricular pressure (LVP)/maximal decreased rate of LVP (&#x000b1;dp/dt<sub>max</sub>). Western blotting assay was utilized to determine the changes in activity of PI3-K/Akt signal pathway</p></sec><sec><title>Examination of hemodynamics</title><p>After 12 h of fasting of both food and water, rats were anesthetized using urethane (25%, 300 mg/kg), and fixed in a plate in supine position. Following the regular skin preparation and disinfection, skin of neck was incised to separate the right common carotid artery (CCA) with a 2-cm segment being freed and exposed. The distal end of CCA was ligated, and the proximal end was clamped with a small bulldog clamp. About 1.5 cm in front of the ligature, polyethylene catheter (containing 0.1% heparin-normal saline; diameter of 1 mm; micro-pressure sensor deployed at the end of catheter) of BL-410S bio-function experiment system (Beijing Temo Technology Co., Ltd., Beijing, China) was inserted through puncture. Then, the bulldog clamp was open, and catheter was guided into the left ventricle through ascending aorta with smooth forceps until the significant flat peak wave in diastolic phase of pressure signal on the screen, indicating that catheter was delivered into the left ventricle. After 10 min of stabilization, indicators were recorded.</p></sec><sec><title>Detection of pAkt and Akt through western blotting assay</title><p>From each group, 4 animals were taken for treatment, and heart tissues were dissected and shifted into the liquid N<sub>2</sub> within 24 h for preservation and later use. In accordance with the regular method, total proteins in heart tissues were extracted for protein quantification with BCA protein quantification kit. Gel was prepared with 10% separation gel and 3% spacer gel, and proteins in cytoplasm were extracted in the mixture of 6X sodium dodecyl sulfate (SDS, 2%) and sample buffer. Five minutes after the temperature reached 95&#x000b0;C, 10 &#x000b5;l samples were loaded for electrophoresis until the bromophenol blue gathered at the bottom of separation gel. Polyvinylidene fluoride membrane was immersed in membrane-transfer buffer for 15 min, and semi-dry membrane transfer was then initiated with gel in contact with the negative electrode of semi-dry transfer cell membrane-transfer apparatus (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and PVDF with the positive electrode under a constant voltage of 15 V for 2&#x02013;3 h. Thereafter, membrane was blocked in 4&#x000b0;C blocking buffer [5% skimmed milk powder and 1&#x003a7; Tris-buffered saline-Tween-20 (TBS-T)] overnight. Membrane was then incubated with primary antibody (Akt, 1:400; pAkt, 1:400) overnight at 4&#x000b0;C, followed by washing. After that, horseradish peroxidase labeled anti-rabbit IgG (1:2,000) was added on the membrane which was later prepared for color development reaction using chemiluminescent method with ECL kit. The X-ray images were prepared for color development. Scanning and identification of images: In this study, the quantitative analysis of grey value was performed with MHImage 1.63 image analysis system.</p><p>Statistical analysis. With Statistical Product and Service Solutions (SPSS 21.0; IBM Corp., Armonk, NY, USA), t-test and one-way analysis of variance (one-way ANOVA) were performed and SNK test was the post hoc test. Measurement data are presented as mean &#x000b1; standard deviation (SD). P&#x0003c;0.05 was set as the critical value.</p></sec></sec></sec><sec sec-type="results"><title>Results</title><sec><title/><sec><title>Observation of general manifestations</title><p>During the whole test, manifestations in the CHF group such as dry and shaggy hair without gloss, lack of energy, drowsiness and hypoactivity, and decline in food were observed sequentially, and in some severe cases, manifestations including massive loss of hair, disturbance in respiration, cyanosis and persistent poor sense on balance. Symptoms of heart failure in varying degrees were also observed in rats of the CEPO group before injection of CEPO, but were ameliorated significantly after medication. However, in the CEPO + LY group, after medication, symptoms of heart failure in varying degrees that were observed before medication had no significant improvement. In addition, symptoms of heart failure of rats in the LY group were more severe than those in the CHF group.</p></sec><sec><title>Hemodynamics indicators</title><p>As shown in <xref rid="tI-etm-0-0-6822" ref-type="table">Table I</xref>, LVSP and &#x000b1;dp/dt<sub>max</sub> in the CHF, CEPO, CEPO + LY and LY groups were significantly lower than those in the control group (P&#x0003c;0.05), while LVEDP and HR in these groups were increased obviously when compared with the control group (P&#x0003c;0.05); in comparison with the CHF, LY and CEPO + LY groups, LVSP and &#x000b1;dp/dt<sub>max</sub> were elevated significantly in the CEPO group (P&#x0003c;0.05) with significant decrease in LVEDP and HR (P&#x0003c;0.05); when compared with the CHF group, LVSP and &#x000b1;dp/dt<sub>max</sub> in the LY group were significantly decreased (P&#x0003c;0.05) with remarkable elevations in LVEDP and HR (P&#x0003c;0.05).</p></sec><sec><title>Comparison of results in western blotting assay</title><p>In comparison with the control group, pAkt levels in CHF, CEPO + LY and LY groups were significantly declined (P&#x0003c;0.05), while that in the CEPO group was significantly higher (P&#x0003c;0.05); in the LY group, pAkt level was significantly lower than that in the CHF group (P&#x0003c;0.05), suggesting that CEPO increased the phosphorylation level of Akt, which was inhibited by LY. Comparisons of Akt levels among groups showed that differences had no statistical significance (<xref rid="f1-etm-0-0-6822" ref-type="fig">Figs. 1</xref> and <xref rid="f2-etm-0-0-6822" ref-type="fig">2</xref>).</p></sec></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>CHF is one of the major causes of death contributed by cardiovascular diseases. Once the cardiac output is decreased to a degree that can hardly satisfy the requirement of the metabolism, a series of organic or functional variations take place, which can threaten the safety and quality of life of humans (<xref rid="b17-etm-0-0-6822" ref-type="bibr">17</xref>). CEPO, as a carbamylated derivative of EPO, has protective effect on myocardial cells but no pro-hematopoietic effect (<xref rid="b18-etm-0-0-6822" ref-type="bibr">18</xref>). Millet <italic>et al</italic> (<xref rid="b19-etm-0-0-6822" ref-type="bibr">19</xref>) reported that in the nerve system, EPO and CEPO can inhibit the opening of mitochondrial permeability transition pore (mPTP) to sustain the membrane potential of mitochondria and calcium homeostasis, thereby reducing the death of cells induced by ischemia. Similarly, other researchers (<xref rid="b20-etm-0-0-6822" ref-type="bibr">20</xref>,<xref rid="b21-etm-0-0-6822" ref-type="bibr">21</xref>) also confirmed that EPO and CEPO have nourishing and protective effect on nerves.</p><p>LVSP mainly reflects the systolic function of myocardium, and decrease of LVSP suggests a decline in systolic function of myocardium; +dp/dt<sub>max</sub> can also indicate the performance of the myocardium in systolic phase almost regardless of the effect of load, and its decrease means that the systolic capability of myocardium is decreased; -dp/dt<sub>max</sub> serves as an indicator of diastolic capability of myocardium, and its decrease reflects that the diastolic capability of myocardium is curbed; LVEDP is used to evaluate the preload of left ventricle and reflect the diastolic capability of myocardium, and the increase of LVEDP shows that the diastolic capability of myocardium is weakened (<xref rid="b22-etm-0-0-6822" ref-type="bibr">22</xref>). In this study, diastolic and systolic capabilities of rats in CHF group were decreased, which, however, were ameliorated after medication of CEPO. In addition, pretreatment of LY blocked the ability of CEPO to ameliorate the heart function. Results of western blotting assay showed that CEPO could elevate the level of pAkt, which was inhibited by treatment of LY, suggesting that CEPO can ameliorate the heart function of CHF rats through PI3-K/Akt signal pathway. Results in this study agreed with those of He <italic>et al</italic> (<xref rid="b23-etm-0-0-6822" ref-type="bibr">23</xref>).</p><p>In addition to the prophylactic effect on apoptosis of myocardial cells and protective effect on myocardial cells, normal activation of PI3-K/Akt signal pathway is also indispensable to other life activities (<xref rid="b2-etm-0-0-6822" ref-type="bibr">2</xref>,<xref rid="b24-etm-0-0-6822" ref-type="bibr">24</xref>&#x02013;<xref rid="b28-etm-0-0-6822" ref-type="bibr">28</xref>). However, excessive activation of this signal pathway may promote the development of cancer (<xref rid="b29-etm-0-0-6822" ref-type="bibr">29</xref>). In this study, LVSP and &#x000b1;dp/dt<sub>max</sub> were decreased and LVEDP and HR increased in the LY group compared with in the CHF group, which might be caused by the blocking effect of LY on PI3-K/Akt signal pathway; this further affected the life activities associated with this signal pathway, and the descended life quality could hardly be sustained, which exacerbated the CHF in rats, further weakening the diastolic and systolic capabilities of the heart.</p><p>In conclusion, CEPO can generate the antagonist effect on CHF in rats through activation of PI3-K/Akt signal pathway.</p></sec></body><back><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><sec><title>Funding</title><p>This study was funded by The Department of Science and Technology of Guangdong Province (project no. 2013B022000103).</p></sec><sec><title>Availability of data and materials</title><p>The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.</p></sec><sec><title>Authors' contributions</title><p>ZH contributed significantly to writing the manuscript and establishment of CHF models. WX and JW helped with animal grouping and treatment. SC conducted examination of hemodynamics. XC performed western blot analysis. All authors read and approved the final manuscript.</p></sec><sec><title>Ethics approval and consent to participate</title><p>The study was approved by the Ethics Committee of The Third Affiliated Hospital of Guangzhou Medical University (Guangzhou, China).</p></sec><sec><title>Patient consent for publication</title><p>Not applicable.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><ref-list><title>References</title><ref id="b1-etm-0-0-6822"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ismailov</surname><given-names>RM</given-names></name></person-group><article-title>Global heart failure rates and erythropoietin</article-title><source>Iran J Med Hypotheses Ideas</source><volume>6</volume><fpage>70</fpage><lpage>74</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.jmhi.2012.08.002</pub-id></element-citation></ref><ref id="b2-etm-0-0-6822"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>XJ</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wan</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Qi</surname><given-names>YJ</given-names></name><name><surname>Huang</surname><given-names>CB</given-names></name></person-group><article-title>Relations of synovial angiogenesis and PTEN/PI3K/AKT signaling pathway in rats with adjuvant arthritis</article-title><source>Zhongguo Gu Shang</source><volume>28</volume><fpage>71</fpage><lpage>74</lpage><year>2015</year><comment>(In Chinese)</comment><?supplied-pmid 25823138?><pub-id pub-id-type="pmid">25823138</pub-id></element-citation></ref><ref id="b3-etm-0-0-6822"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polat</surname><given-names>N</given-names></name><name><surname>Oz</surname><given-names>F</given-names></name><name><surname>Bayk&#x00131;z</surname><given-names>D</given-names></name><name><surname>Cizgici</surname><given-names>AY</given-names></name><name><surname>Altun</surname><given-names>I</given-names></name><name><surname>Bu&#x0011f;ra</surname><given-names>Z</given-names></name><name><surname>Umman</surname><given-names>B</given-names></name><name><surname>Tufan</surname><given-names>F</given-names></name><name><surname>Oflaz</surname><given-names>H</given-names></name></person-group><article-title>Predictors of functional capacity in younger and elderly chronic heart failure patients: An observational study</article-title><source>Anadolu Kardiyol Derg</source><volume>13</volume><fpage>778</fpage><lpage>783</lpage><year>2013</year><?supplied-pmid 24172836?><pub-id pub-id-type="pmid">24172836</pub-id></element-citation></ref><ref id="b4-etm-0-0-6822"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwanami</surname><given-names>J</given-names></name><name><surname>Mogi</surname><given-names>M</given-names></name><name><surname>Iwai</surname><given-names>M</given-names></name><name><surname>Horiuchi</surname><given-names>M</given-names></name></person-group><article-title>Inhibition of the renin-angiotensin system and target organ protection</article-title><source>Hypertens Res</source><volume>32</volume><fpage>229</fpage><lpage>237</lpage><year>2009</year><pub-id pub-id-type="doi">10.1038/hr.2009.5</pub-id><?supplied-pmid 19262496?><pub-id pub-id-type="pmid">19262496</pub-id></element-citation></ref><ref id="b5-etm-0-0-6822"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>N</given-names></name><name><surname>Mukai</surname><given-names>HY</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name></person-group><article-title>In vivo regulation of erythropoiesis by chemically inducible dimerization of the erythropoietin receptor intracellular domain</article-title><source>PLoS One</source><volume>10</volume><fpage>e0119442</fpage><year>2015</year><pub-id pub-id-type="doi">10.1371/journal.pone.0119442</pub-id><?supplied-pmid 25790231?><pub-id pub-id-type="pmid">25790231</pub-id></element-citation></ref><ref id="b6-etm-0-0-6822"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>LJ</given-names></name><name><surname>Wu</surname><given-names>XH</given-names></name></person-group><article-title>Effects of erythropoietin on cardiomyocyte apoptosis and endoplasmic reticulum stress-related proteins in neonatal rats with asphyxia</article-title><source>Zhongguo Dang Dai Er Ke Za Zhi</source><volume>15</volume><fpage>890</fpage><lpage>895</lpage><year>2013</year><comment>(In Chinese)</comment><?supplied-pmid 24131844?><pub-id pub-id-type="pmid">24131844</pub-id></element-citation></ref><ref id="b7-etm-0-0-6822"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>ZY</given-names></name><name><surname>Yeh</surname><given-names>MK</given-names></name><name><surname>Chiang</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>YH</given-names></name><name><surname>Lu</surname><given-names>DW</given-names></name></person-group><article-title>Erythropoietin protects adult retinal ganglion cells against NMDA-, trophic factor withdrawal-, and TNF-&#x003b1;-induced damage</article-title><source>PLoS One</source><volume>8</volume><fpage>e55291</fpage><year>2013</year><pub-id pub-id-type="doi">10.1371/journal.pone.0055291</pub-id><?supplied-pmid 23383140?><pub-id pub-id-type="pmid">23383140</pub-id></element-citation></ref><ref id="b8-etm-0-0-6822"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doue</surname><given-names>T</given-names></name><name><surname>Ohtsuki</surname><given-names>K</given-names></name><name><surname>Ogawa</surname><given-names>K</given-names></name><name><surname>Ueda</surname><given-names>M</given-names></name><name><surname>Azuma</surname><given-names>A</given-names></name><name><surname>Saji</surname><given-names>H</given-names></name><name><surname>Strauss</surname><given-names>HW</given-names></name><name><surname>Matsubara</surname><given-names>H</given-names></name></person-group><article-title>Cardioprotective effects of erythropoietin in rats subjected to ischemia-reperfusion injury: Assessment of infarct size with 99mTc-annexin V</article-title><source>J Nucl Med</source><volume>49</volume><fpage>1694</fpage><lpage>1700</lpage><year>2008</year><pub-id pub-id-type="doi">10.2967/jnumed.107.050260</pub-id><?supplied-pmid 18794258?><pub-id pub-id-type="pmid">18794258</pub-id></element-citation></ref><ref id="b9-etm-0-0-6822"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name></person-group><article-title>High-dose erythropoietin in acute ST-segment elevation myocardial infarction: A meta-analysis of randomized controlled trials</article-title><source>Am J Cardiovasc Drugs</source><volume>13</volume><fpage>435</fpage><lpage>442</lpage><year>2013</year><pub-id pub-id-type="doi">10.1007/s40256-013-0042-3</pub-id><?supplied-pmid 24097294?><pub-id pub-id-type="pmid">24097294</pub-id></element-citation></ref><ref id="b10-etm-0-0-6822"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minamino</surname><given-names>T</given-names></name><name><surname>Toba</surname><given-names>K</given-names></name><name><surname>Higo</surname><given-names>S</given-names></name><name><surname>Nakatani</surname><given-names>D</given-names></name><name><surname>Hikoso</surname><given-names>S</given-names></name><name><surname>Umegaki</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Sawa</surname><given-names>Y</given-names></name><name><surname>Aizawa</surname><given-names>Y</given-names></name><name><surname>Komuro</surname><given-names>I</given-names></name></person-group><collab collab-type="corp-author">EPO-AMI-II study investigators</collab><article-title>Design and rationale of low-dose erythropoietin in patients with ST-segment elevation myocardial infarction (EPO-AMI-II study): A randomized controlled clinical trial</article-title><source>Cardiovasc Drugs Ther</source><volume>26</volume><fpage>409</fpage><lpage>416</lpage><year>2012</year><pub-id pub-id-type="doi">10.1007/s10557-012-6410-4</pub-id><?supplied-pmid 22940818?><pub-id pub-id-type="pmid">22940818</pub-id></element-citation></ref><ref id="b11-etm-0-0-6822"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiordaliso</surname><given-names>F</given-names></name><name><surname>Chimenti</surname><given-names>S</given-names></name><name><surname>Staszewsky</surname><given-names>L</given-names></name><name><surname>Bai</surname><given-names>A</given-names></name><name><surname>Carlo</surname><given-names>E</given-names></name><name><surname>Cuccovillo</surname><given-names>I</given-names></name><name><surname>Doni</surname><given-names>M</given-names></name><name><surname>Mengozzi</surname><given-names>M</given-names></name><name><surname>Tonelli</surname><given-names>R</given-names></name><name><surname>Ghezzi</surname><given-names>P</given-names></name><etal/></person-group><article-title>A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury</article-title><source>Proc Natl Acad Sci USA</source><volume>102</volume><fpage>2046</fpage><lpage>2051</lpage><year>2005</year><pub-id pub-id-type="doi">10.1073/pnas.0409329102</pub-id><?supplied-pmid 15671158?><pub-id pub-id-type="pmid">15671158</pub-id></element-citation></ref><ref id="b12-etm-0-0-6822"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kretz</surname><given-names>A</given-names></name><name><surname>Happold</surname><given-names>CJ</given-names></name><name><surname>Marticke</surname><given-names>JK</given-names></name><name><surname>Isenmann</surname><given-names>S</given-names></name></person-group><article-title>Erythropoietin promotes regeneration of adult CNS neurons via Jak2/Stat3 and PI3K/AKT pathway activation</article-title><source>Mol Cell Neurosci</source><volume>29</volume><fpage>569</fpage><lpage>579</lpage><year>2005</year><pub-id pub-id-type="doi">10.1016/j.mcn.2005.04.009</pub-id><?supplied-pmid 15936213?><pub-id pub-id-type="pmid">15936213</pub-id></element-citation></ref><ref id="b13-etm-0-0-6822"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Lv</surname><given-names>S</given-names></name><name><surname>Mi</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name></person-group><article-title>Neuroprotective effect of miR-665 against sevoflurane anesthesia-induced cognitive dysfunction in rats through PI3K/Akt signaling pathway by targeting insulin-like growth factor 2</article-title><source>Am J Transl Res</source><volume>9</volume><fpage>1344</fpage><lpage>1356</lpage><year>2017</year><?supplied-pmid 28386360?><pub-id pub-id-type="pmid">28386360</pub-id></element-citation></ref><ref id="b14-etm-0-0-6822"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gasparotto</surname><given-names>EPL</given-names></name><name><surname>Tognon</surname><given-names>R</given-names></name><name><surname>Ferreira</surname><given-names>AF</given-names></name><name><surname>Oliveira</surname><given-names>GLV</given-names></name><name><surname>Palma</surname><given-names>PVB</given-names></name><name><surname>Zanichelli</surname><given-names>MA</given-names></name><name><surname>Souto</surname><given-names>EX</given-names></name><name><surname>Velano</surname><given-names>CEE</given-names></name><name><surname>Carrara</surname><given-names>RCV</given-names></name><name><surname>Kashima</surname><given-names>S</given-names></name><etal/></person-group><article-title>Deregulated expression of <italic>A1, Bcl-2, Bcl-xL</italic>, and <italic>Mcl-1</italic> antiapoptotic proteins and Bid, Bad, and Bax proapoptotic genes in polycythemia vera patients</article-title><source>Braz J Pharm Sci</source><volume>47</volume><fpage>873</fpage><lpage>886</lpage><year>2011</year><pub-id pub-id-type="doi">10.1590/S1984-82502011000400025</pub-id></element-citation></ref><ref id="b15-etm-0-0-6822"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sattarzadeh</surname><given-names>R</given-names></name><name><surname>Tavoosi</surname><given-names>A</given-names></name><name><surname>Tajik</surname><given-names>P</given-names></name></person-group><article-title>Echocardiographic estimation of left ventricular filling pressures in patients with mitral valve stenosis</article-title><source>Cardiovasc J Afr</source><volume>25</volume><fpage>34</fpage><lpage>39</lpage><year>2014</year><pub-id pub-id-type="doi">10.5830/CVJA-2013-088</pub-id><?supplied-pmid 24626519?><pub-id pub-id-type="pmid">24626519</pub-id></element-citation></ref><ref id="b16-etm-0-0-6822"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Takemura</surname><given-names>G</given-names></name><name><surname>Okada</surname><given-names>H</given-names></name><name><surname>Miyata</surname><given-names>S</given-names></name><name><surname>Maruyama</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Higuchi</surname><given-names>M</given-names></name><name><surname>Minatoguchi</surname><given-names>S</given-names></name><name><surname>Fujiwara</surname><given-names>T</given-names></name><name><surname>Fujiwara</surname><given-names>H</given-names></name></person-group><article-title>Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure</article-title><source>Cardiovasc Res</source><volume>71</volume><fpage>684</fpage><lpage>694</lpage><year>2006</year><pub-id pub-id-type="doi">10.1016/j.cardiores.2006.06.003</pub-id><?supplied-pmid 16828072?><pub-id pub-id-type="pmid">16828072</pub-id></element-citation></ref><ref id="b17-etm-0-0-6822"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martins</surname><given-names>QC</given-names></name><name><surname>Aliti</surname><given-names>G</given-names></name><name><surname>Rabelo</surname><given-names>ER</given-names></name></person-group><article-title>Decreased cardiac output: Clinical validation in patients with decompensated heart failure</article-title><source>Int J Nurs Terminol Classif</source><volume>21</volume><fpage>156</fpage><lpage>165</lpage><year>2010</year><pub-id pub-id-type="doi">10.1111/j.1744-618X.2010.01161.x</pub-id><?supplied-pmid 20977620?><pub-id pub-id-type="pmid">20977620</pub-id></element-citation></ref><ref id="b18-etm-0-0-6822"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Plane</surname><given-names>JM</given-names></name><name><surname>Pleasure</surname><given-names>DE</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name></person-group><article-title>Neuroprotective potential of erythropoietin and its derivative carbamylated erythropoietin in periventricular leukomalacia</article-title><source>Exp Neurol</source><volume>230</volume><fpage>227</fpage><lpage>239</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.expneurol.2011.04.021</pub-id><?supplied-pmid 21596035?><pub-id pub-id-type="pmid">21596035</pub-id></element-citation></ref><ref id="b19-etm-0-0-6822"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millet</surname><given-names>A</given-names></name><name><surname>Bouzat</surname><given-names>P</given-names></name><name><surname>Trouve-Buisson</surname><given-names>T</given-names></name><name><surname>Batandier</surname><given-names>C</given-names></name><name><surname>Pernet-Gallay</surname><given-names>K</given-names></name><name><surname>Gaide-Chevronnay</surname><given-names>L</given-names></name><name><surname>Barbier</surname><given-names>EL</given-names></name><name><surname>Debillon</surname><given-names>T</given-names></name><name><surname>Fontaine</surname><given-names>E</given-names></name><name><surname>Payen</surname><given-names>JF</given-names></name></person-group><article-title>Erythropoietin and its derivates modulate mitochondrial dysfunction after diffuse traumatic brain injury</article-title><source>J Neurotrauma</source><volume>33</volume><fpage>1625</fpage><lpage>1633</lpage><year>2016</year><pub-id pub-id-type="doi">10.1089/neu.2015.4160</pub-id><?supplied-pmid 26530102?><pub-id pub-id-type="pmid">26530102</pub-id></element-citation></ref><ref id="b20-etm-0-0-6822"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Bai</surname><given-names>ZY</given-names></name><name><surname>Zhang</surname><given-names>FY</given-names></name><name><surname>Xu</surname><given-names>XY</given-names></name></person-group><article-title>Neuroprotection of herbs promoting EPO on cerebral ischemia</article-title><source>Zhongguo Zhong Yao Za Zhi</source><volume>40</volume><fpage>2265</fpage><lpage>2271</lpage><year>2015</year><comment>(In Chinese)</comment><?supplied-pmid 26591507?><pub-id pub-id-type="pmid">26591507</pub-id></element-citation></ref><ref id="b21-etm-0-0-6822"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>YX</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Si</surname><given-names>MS</given-names></name><name><surname>Mo</surname><given-names>JJ</given-names></name><name><surname>Qiao</surname><given-names>SC</given-names></name><name><surname>Lai</surname><given-names>HC</given-names></name></person-group><article-title>The roles of PI3K/Akt signaling pathway in regulating MC3T3-E1 preosteoblast proliferation and differentiation on SLA and SLActive titanium surfaces</article-title><source>J Biomed Mater Res A</source><volume>101</volume><fpage>748</fpage><lpage>754</lpage><year>2013</year><pub-id pub-id-type="doi">10.1002/jbm.a.34377</pub-id><?supplied-pmid 22941963?><pub-id pub-id-type="pmid">22941963</pub-id></element-citation></ref><ref id="b22-etm-0-0-6822"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>JT</given-names></name><name><surname>Grbic</surname><given-names>M</given-names></name><name><surname>Sigwart</surname><given-names>U</given-names></name></person-group><article-title>Left atrial and left ventricular diastolic function during acute myocardial ischaemia</article-title><source>Br Heart J</source><volume>68</volume><fpage>377</fpage><lpage>381</lpage><year>1992</year><pub-id pub-id-type="doi">10.1136/hrt.68.10.377</pub-id><?supplied-pmid 1449920?><pub-id pub-id-type="pmid">1449920</pub-id></element-citation></ref><ref id="b23-etm-0-0-6822"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>H</given-names></name><name><surname>Qiao</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name></person-group><article-title>Carbamylated erythropoietin attenuates cardiomyopathy via PI3K/Akt activation in rats with diabetic cardiomyopathy</article-title><source>Exp Ther Med</source><volume>6</volume><fpage>567</fpage><lpage>573</lpage><year>2013</year><pub-id pub-id-type="doi">10.3892/etm.2013.1134</pub-id><?supplied-pmid 24137228?><pub-id pub-id-type="pmid">24137228</pub-id></element-citation></ref><ref id="b24-etm-0-0-6822"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueba</surname><given-names>H</given-names></name><name><surname>Brines</surname><given-names>M</given-names></name><name><surname>Yamin</surname><given-names>M</given-names></name><name><surname>Umemoto</surname><given-names>T</given-names></name><name><surname>Ako</surname><given-names>J</given-names></name><name><surname>Momomura</surname><given-names>S</given-names></name><name><surname>Cerami</surname><given-names>A</given-names></name><name><surname>Kawakami</surname><given-names>M</given-names></name></person-group><article-title>Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin</article-title><source>Proc Natl Acad Sci USA</source><volume>107</volume><fpage>14357</fpage><lpage>14362</lpage><year>2010</year><pub-id pub-id-type="doi">10.1073/pnas.1003019107</pub-id><?supplied-pmid 20660739?><pub-id pub-id-type="pmid">20660739</pub-id></element-citation></ref><ref id="b25-etm-0-0-6822"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Pan</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>JNK/PI3K/Akt signaling pathway is involved in myocardial ischemia/reperfusion injury in diabetic rats: effects of salvianolic acid A intervention</article-title><source>Am J Transl Res</source><volume>8</volume><fpage>2534</fpage><lpage>2548</lpage><year>2016</year><?supplied-pmid 27398138?><pub-id pub-id-type="pmid">27398138</pub-id></element-citation></ref><ref id="b26-etm-0-0-6822"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Oliveira</surname><given-names>MR</given-names></name><name><surname>Ferreira</surname><given-names>GC</given-names></name><name><surname>Schuck</surname><given-names>PF</given-names></name><name><surname>Dal Bosco</surname><given-names>SM</given-names></name></person-group><article-title>Role for the PI3K/Akt/Nrf2 signaling pathway in the protective effects of carnosic acid against methylglyoxal-induced neurotoxicity in SH-SY5Y neuroblastoma cells</article-title><source>Chem Biol Interact</source><volume>242</volume><fpage>396</fpage><lpage>406</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.cbi.2015.11.003</pub-id><?supplied-pmid 26577515?><pub-id pub-id-type="pmid">26577515</pub-id></element-citation></ref><ref id="b27-etm-0-0-6822"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Han</surname><given-names>P</given-names></name></person-group><article-title>The effect of <italic>tianmai xiaoke pian</italic> on insulin resistance through PI3-K/AKT signal pathway</article-title><source>J Diabetes Res</source><volume>2016</volume><fpage>9261259</fpage><year>2016</year><pub-id pub-id-type="doi">10.1155/2016/9261259</pub-id><?supplied-pmid 26640808?><pub-id pub-id-type="pmid">26640808</pub-id></element-citation></ref><ref id="b28-etm-0-0-6822"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cen</surname><given-names>L</given-names></name><name><surname>Hsieh</surname><given-names>FC</given-names></name><name><surname>Lin</surname><given-names>HJ</given-names></name><name><surname>Chen</surname><given-names>CS</given-names></name><name><surname>Qualman</surname><given-names>SJ</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name></person-group><article-title>PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound</article-title><source>Br J Cancer</source><volume>97</volume><fpage>785</fpage><lpage>791</lpage><year>2007</year><pub-id pub-id-type="doi">10.1038/sj.bjc.6603952</pub-id><?supplied-pmid 17848913?><pub-id pub-id-type="pmid">17848913</pub-id></element-citation></ref><ref id="b29-etm-0-0-6822"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Lou</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>C</given-names></name><name><surname>Lou</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Activation of the JAK-STAT3 pathway is associated with the growth of colorectal carcinoma cells</article-title><source>Oncol Rep</source><volume>31</volume><fpage>335</fpage><lpage>341</lpage><year>2014</year><pub-id pub-id-type="doi">10.3892/or.2013.2858</pub-id><?supplied-pmid 24253664?><pub-id pub-id-type="pmid">24253664</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-etm-0-0-6822" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Expression of Akt and pAkt in rats of all groups. Expression of Akt and pAkt in rats of all groups through western blotting assay. Akt, protein kinase B; pAkt, phosphorylated Akt; CHF, chronic heart failure; CEPO, carbamylated erythropoietin; LY, LY294002.</p></caption><graphic xlink:href="etm-16-06-5161-g00"/></fig><fig id="f2-etm-0-0-6822" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Statistical diagram of relative expression of pAkt. <sup>#</sup>P&#x0003c;0.05 in comparison with the CEPO group; <sup>&#x025b3;</sup>P&#x0003c;0.05 in comparison with the LY group; *P&#x0003c;0.05 in comparison with the CHF group; <sup>&#x025b2;</sup>P&#x0003c;0.05 in comparison with the control group. Akt, protein kinase B; pAkt, phosphorylated Akt; CHF, chronic heart failure; CEPO, carbamylated erythropoietin; LY, LY294002.</p></caption><graphic xlink:href="etm-16-06-5161-g01"/></fig><table-wrap id="tI-etm-0-0-6822" orientation="portrait" position="float"><label>Table I.</label><caption><p>Comparison of the hemodynamics indicators among groups (mean &#x000b1; SD).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Control group</th><th align="center" valign="bottom" rowspan="1" colspan="1">CHF group</th><th align="center" valign="bottom" rowspan="1" colspan="1">CEPO group</th><th align="center" valign="bottom" rowspan="1" colspan="1">CEPO+LY group</th><th align="center" valign="bottom" rowspan="1" colspan="1">LY group</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">n</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">23</td><td align="center" valign="top" rowspan="1" colspan="1">23</td><td align="center" valign="top" rowspan="1" colspan="1">23</td><td align="center" valign="top" rowspan="1" colspan="1">23</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LVSP (mmHg)</td><td align="center" valign="top" rowspan="1" colspan="1">134.71&#x000b1;6.31</td><td align="center" valign="top" rowspan="1" colspan="1">108.40&#x000b1;8.24<sup><xref rid="tfn1-etm-0-0-6822" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">119.72&#x000b1;7.84<sup><xref rid="tfn1-etm-0-0-6822" ref-type="table-fn">a</xref><xref rid="tfn2-etm-0-0-6822" ref-type="table-fn">b</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">112.48&#x000b1;8.01<sup><xref rid="tfn1-etm-0-0-6822" ref-type="table-fn">a</xref><xref rid="tfn3-etm-0-0-6822" ref-type="table-fn">c</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">97.2&#x000b1;6.76<sup><xref rid="tfn1-etm-0-0-6822" ref-type="table-fn">a</xref>&#x02013;<xref rid="tfn3-etm-0-0-6822" ref-type="table-fn">c</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">+dp/dt<sub>max</sub> (mmHg/sec)</td><td align="center" valign="top" rowspan="1" colspan="1">4444.54&#x000b1;230.56</td><td align="center" valign="top" rowspan="1" colspan="1">2965.74&#x000b1;235.41<sup><xref rid="tfn1-etm-0-0-6822" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">3721.50&#x000b1;200.07<sup><xref rid="tfn1-etm-0-0-6822" ref-type="table-fn">a</xref><xref rid="tfn2-etm-0-0-6822" ref-type="table-fn">b</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">3328.64&#x000b1;210.43<sup><xref rid="tfn1-etm-0-0-6822" ref-type="table-fn">a</xref><xref rid="tfn3-etm-0-0-6822" ref-type="table-fn">c</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">2794.47&#x000b1;198.52<sup><xref rid="tfn1-etm-0-0-6822" ref-type="table-fn">a</xref>&#x02013;<xref rid="tfn3-etm-0-0-6822" ref-type="table-fn">c</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">-dp/dt<sub>max</sub> (mmHg/sec)</td><td align="center" valign="top" rowspan="1" colspan="1">3926.60&#x000b1;208.78</td><td align="center" valign="top" rowspan="1" colspan="1">2879.95&#x000b1;219.93<sup><xref rid="tfn1-etm-0-0-6822" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">3343.28&#x000b1;207.41<sup><xref rid="tfn1-etm-0-0-6822" ref-type="table-fn">a</xref><xref rid="tfn2-etm-0-0-6822" ref-type="table-fn">b</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">3014.7&#x000b1;209.87<sup><xref rid="tfn1-etm-0-0-6822" ref-type="table-fn">a</xref><xref rid="tfn3-etm-0-0-6822" ref-type="table-fn">c</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">2689.98&#x000b1;207.34<sup><xref rid="tfn1-etm-0-0-6822" ref-type="table-fn">a</xref>&#x02013;<xref rid="tfn3-etm-0-0-6822" ref-type="table-fn">c</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LEVDP (mmHg)</td><td align="center" valign="top" rowspan="1" colspan="1">5.36&#x000b1;0.78</td><td align="center" valign="top" rowspan="1" colspan="1">19.46&#x000b1;1.17<sup><xref rid="tfn1-etm-0-0-6822" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">11.70&#x000b1;1.14<sup><xref rid="tfn1-etm-0-0-6822" ref-type="table-fn">a</xref><xref rid="tfn2-etm-0-0-6822" ref-type="table-fn">b</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">14.43&#x000b1;1.07<sup><xref rid="tfn1-etm-0-0-6822" ref-type="table-fn">a</xref><xref rid="tfn3-etm-0-0-6822" ref-type="table-fn">c</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">22.62&#x000b1;1.21<sup><xref rid="tfn1-etm-0-0-6822" ref-type="table-fn">a</xref>&#x02013;<xref rid="tfn3-etm-0-0-6822" ref-type="table-fn">c</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HR (beat/min)</td><td align="center" valign="top" rowspan="1" colspan="1">340.43&#x000b1;11.61</td><td align="center" valign="top" rowspan="1" colspan="1">416.11&#x000b1;13.63<sup><xref rid="tfn1-etm-0-0-6822" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">388.84&#x000b1;11.85<sup><xref rid="tfn1-etm-0-0-6822" ref-type="table-fn">a</xref><xref rid="tfn2-etm-0-0-6822" ref-type="table-fn">b</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">427.84&#x000b1;12.43<sup><xref rid="tfn1-etm-0-0-6822" ref-type="table-fn">a</xref><xref rid="tfn3-etm-0-0-6822" ref-type="table-fn">c</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">470.46&#x000b1;11.93<sup><xref rid="tfn1-etm-0-0-6822" ref-type="table-fn">a</xref>&#x02013;<xref rid="tfn3-etm-0-0-6822" ref-type="table-fn">c</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="tfn1-etm-0-0-6822"><label>a</label><p>P&#x0003c;0.05 in comparison with control group</p></fn><fn id="tfn2-etm-0-0-6822"><label>b</label><p>P&#x0003c;0.05 in comparison with CHF group</p></fn><fn id="tfn3-etm-0-0-6822"><label>c</label><p>P&#x0003c;0.05 in comparison with CEPO group. CHF, chronic heart failure; CEPO, carbamylated erythropoietin; LY, LY294002; LVSP, left ventricular systolic pressure; LEVDP, left ventricular end-diastolic pressure; HR, heart rate.</p></fn></table-wrap-foot></table-wrap></floats-group></article>